CTRI/2019/05/019366已完成未知
A Randomized, Double Blinded, Crossover designed, Placebo Controlled Study to evaluate the effects of supplement REPHYLL on delayed onset muscle soreness (DOMS) in humans - DOMS-2
Aurea Biolabs P Ltd0 个研究点目标入组 20 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Subject has provided written and dated informed consent to participate in the study. Subject is willing and able to comply with the protocol. Subject is a male between 19 and 29 years of age, inclusive. Subject is in good health as determined by a health history questionnaire. Subject is untrained in resistance/power exercise
排除标准
- •Subject is participating in another clinical trial or has received an investigational product within thirty days prior to enrollment. Subject has a history of alcohol or other drug abuse in the past year. Subject has a significant history or current presence of treated or untreated bleeding disorder, diabetes mellitus, high blood pressure (BP) [systolic BP > 140 and/or diastolic BP > 90], thyroid disease, tachyarrhythmia, heart disease, kidney disease, or liver disease. Subject currently suffers from a sleep disorder and/or has a known history of (or is currently being treated for) clinical depression, eating disorder(s) or any other psychiatric condition(s), which in the opinion of the investigator, might put the subject at risk and/or confound the results of the study. Subject has a known allergy or sensitivity to any ingredient in the test product. Subject has any medical condition or uses any medication, nutritional product, dietary supplement or program, which in the opinion of the investigator, might interfere with the conduct of the study or place the subject at risk. Subject has a history of difficulty swallowing large pills or tablets. Subject has used creatine within 9 weeks prior to screening. Subject has a history of orthopedic injury or surgery within the last year. Subject has any physical condition considered a contra-indication to the type of exercise performed in the study. Subject has had an abnormal resting ECG. Investigator is uncertain about subjectâ??s capability or willingness to comply with the protocol requirements.
研究者
相似试验
已完成
3 期
A clinical trial comparing bronchodilator effects of two drugs,Tiotropium Bromide and Formoterol Fumarate each over 24 hours in subjects with Asthma.CTRI/2008/091/000306Chest Research Foundation30
已完成
不适用
To study effect of food Supplement on blood parameters, after consuming alcoholic drink.CTRI/2019/11/022060PrARAS BIOSCIENCES PVT LTD30
进行中（未招募）
不适用
A Single Center, Double Blind, Randomized Crossover Study Evaluating the Bioequivalence of VIAject®7 compared to VIAject™25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects with Type 1 Diabetes MellitusMedDRA version: 9.1Level: LLTClassification code 10045238Term: Type I diabetes mellitus without mention of complicationType 1 Diabetes MellitusEUCTR2009-012082-54-DEBIODEL inc.
进行中（未招募）
不适用
A Single-Center, Double Blind, Randomized Crossover Study Evaluating Injection Site Toleration of VIAject® 7, VIAject® 25 and Insulin Lispro in Subjects with Type 1 or Type 2 Diabetes MellitusType 1 or Type 2 Diabetes MellitusMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2009-013264-39-DEBIODEL inc.
进行中（未招募）
不适用
A prospective, randomized, double blinded, crossover, two-treatment, two-sequence, short term pharmacokinetic, pharmacodynamic and tolerability, single centre study to compare AOP200704 vs. Esmolol in healthy subjects.healthy male and female volunteers, intended for the treatment of dobutamine-induced tachycardiaMedDRA version: 12.1Level: LLTClassification code 10040752Term: Sinus tachycardiaEUCTR2010-023311-34-CZAOP Orphan Pharmaceuticals AG